Aluminum Oxide Berberis Vulgaris Root Bark Caustic
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Aluminum Oxide Berberis Vulgaris Root Bark Caustic
- Multi-Component Homeopathic Formula (Saw Palmetto / Berberis Vulgaris / Lytta Vesicatoria): Repurposing Evaluation Not Feasible
Multi-Component Homeopathic Formula (Saw Palmetto / Berberis Vulgaris / Lytta Vesicatoria): Repurposing Evaluation Not Feasible
One-Sentence Summary
This submission covers an 8-ingredient homeopathic combination — Aluminum Oxide, Berberis Vulgaris Root Bark, Causticum, Chondrodendron Tomentosum Root, Lead, Lytta Vesicatoria, Nitric Acid, and Saw Palmetto — for which no registered product indications, DrugBank mapping, or mechanism-of-action data exist. The TxGNN model was unable to generate any repurposing predictions, as the multi-component homeopathic nature prevents single-entity matching in the knowledge graph. With 0 clinical trials, 0 publications, and 0 regulatory approvals retrieved, evaluation is not currently feasible.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on record |
| Predicted New Indication | None — TxGNN prediction unavailable |
| TxGNN Prediction Score | N/A |
| Evidence Level | Cannot be determined |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why Evaluation Is Not Currently Feasible
TxGNN returned no predictions for this compound. The multi-component homeopathic formulation cannot be resolved to a single DrugBank node, which is a prerequisite for both the knowledge-graph (KG) and deep-learning (DL) prediction pipelines. Without a prediction anchor, there is no repurposing hypothesis to assess.
The formula combines herbal ingredients with established literature (Saw Palmetto for benign prostatic hyperplasia; Berberis Vulgaris for urinary and metabolic conditions) and classical homeopathic remedies (Causticum, Lytta Vesicatoria, Nitric Acid). Collectively, the component profile suggests a urogenital focus, but no unified indication has been confirmed.
Two ingredients introduce acute toxicological concerns before any efficacy evaluation can proceed: Lead is a well-characterised human toxin with no established safe dose, and Chondrodendron Tomentosum Root is the botanical source of curare alkaloids (tubocurarine), which carry neuromuscular-blocking risks. Additionally, Lytta Vesicatoria (Spanish fly) contains cantharidin — a vesicant and nephrotoxin. These signals must be fully characterised before development activity is considered.
No mechanism-of-action data is available for the combination as a whole. Individual components such as berberine (from Berberis Vulgaris) and beta-sitosterol (from Saw Palmetto) have DrugBank entries and could serve as surrogate anchors for component-level TxGNN queries.
Safety Considerations
⚠️ Critical Safety Flags (requires resolution before any evaluation)
- Lead: A confirmed human neurotoxin and carcinogen. Any product listing Lead as an ingredient must demonstrate compliance with heavy metal limits (e.g., USP <232>, ICH Q3D, or equivalent) prior to clinical consideration.
- Lytta Vesicatoria (Cantharides): Contains cantharidin, a nephrotoxin and vesicant. Systemic exposure carries risk of haemorrhagic cystitis, renal failure, and mucosal injury.
- Chondrodendron Tomentosum Root: Source of tubocurarine-class alkaloids (neuromuscular blocking agents). Uncharacterised dose in this formulation.
No formal key warnings, contraindications, or drug–drug interaction data were returned for this combination. Please refer to the package inserts of individual components for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model produced no repurposing predictions for this multi-component homeopathic combination, and no regulatory approvals exist in any reviewed jurisdiction. The presence of Lead, cantharidin-containing Lytta Vesicatoria, and curare-source Chondrodendron introduces significant unresolved safety signals that must be addressed before any development pathway is considered.
To proceed, the following is needed:
- Jurisdiction clarification: Determine whether this formula is registered as a homeopathic product in any jurisdiction (e.g., EU Article 16 simplified registration, FDA homeopathic OTC, Health Canada Natural Health Product).
- Ingredient-level decomposition: Resolve each of the 8 components to individual DrugBank / PubChem CID entries to enable component-level TxGNN queries.
- Safety characterisation:
- Lead content assay and compliance with heavy metal regulatory limits.
- Cantharidin quantification and toxicological risk assessment for Lytta Vesicatoria.
- Tubocurarine-class alkaloid profiling for Chondrodendron Tomentosum Root.
- Targeted re-prediction: Re-run TxGNN on pharmacologically tractable individual components with known DrugBank IDs — e.g., berberine (DB04115) for Berberis Vulgaris, and Serenoa repens extract / beta-sitosterol for Saw Palmetto — to generate component-specific repurposing candidates.
- Clinical context documentation: Clarify the intended therapeutic area (likely urogenital/prostate based on component profile) to scope any future literature or trial search.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.